Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Piper Sandler Maintains Overweight on Day One Biopharmaceutical, Raises Price Target to $45

Piper Sandler Maintains Overweight on Day One Biopharmaceutical, Raises Price Target to $45

Piper Sandler analyst Joseph Catanzaro maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight and raises the price target from $40 to $45.

byBenzinga Newsdesk

January 9, 2023

1 minute read

Piper Sandler analyst Joseph Catanzaro maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight and raises the price target from $40 to $45.

LianBio Touts Positive Data From Bristol Myers-Partnered Heart Drug In Chinese Patients

By Vandana Singh

April 26, 1:56 PM

LianBio (NASDAQ: LIAN) announced

BMY

LiveOne Updates On PodcastOne’s Planned Spin-Out; Strengthens Balance Sheet; Increases Special Dividend From 12% To ~19%; Repays $3M Of PodcastOne’s Convertible Debt

By Benzinga Newsdesk

June 14, 8:54 AM

- PodcastOne's S-1 Registration Statement Declared Effective by the SEC- Repays $3 Million of PodcastOne's convertible debt- Increases Special Dividend from 12% to ~19%- Extends Record Date to Coincide with

LVO